Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2903
Source ID: NCT01398592
Associated Drug: Vildagliptin
Title: Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy
Acronym: FPG-VISIT
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG: Vildagliptin|DRUG: Sitagliptin
Outcome Measures: Primary: demonstrate that the FPG after 14 days of treatment with Vildagliptin is superior to the FPG after 14 days of treatment with Sitagliptin, Fasting Plasma Glucose measured on day 14., 14 days | Secondary: To assess the difference in FPG between vildagliptin and sitagliptin in patients with type 2 diabetes mellitus on concomitant treatment with metformin, Fasting Plasma Glucose on day 14 analyzed descriptively., 14 days
Sponsor/Collaborators: Sponsor: Novartis Pharmaceuticals
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE4
Enrollment: 187
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2011-06
Completion Date: 2012-06
Results First Posted:
Last Update Posted: 2013-02-12
Locations: Novartis Investigative Site, Bad Oeynhausen, 32549, Germany|Novartis Investigative Site, Berlin, 12347, Germany|Novartis Investigative Site, Berlin, 13597, Germany|Novartis Investigative Site, Berlin, 14089, Germany|Novartis Investigative Site, Celle, 29221, Germany|Novartis Investigative Site, Hannover, 30165, Germany|Novartis Investigative Site, Hannover, 30167, Germany|Novartis Investigative Site, Kassel, 34117, Germany|Novartis Investigative Site, Kirchhain, 35274, Germany|Novartis Investigative Site, Lehrte, 31275, Germany|Novartis Investigative Site, Mülheim, 45468, Germany|Novartis Investigative Site, Oberhausen, 46049, Germany|Novartis Investigative Site, Osnabrück, 49080, Germany|Novartis Investigative Site, Potsdam, 14469, Germany|Novartis Investigative Site, Stuttgart, 70378, Germany
URL: https://clinicaltrials.gov/show/NCT01398592